Physician

Ashish Haryani, MD

According to 2025 Medicare claims, Ashish Haryani, MD (NPI: 1245556547) practices advanced heart failure and transplant cardiology in the Chicago-Naperville-Schaumburg, IL market, with the plurality of this provider's patient population coming from Cook, IL. This provider's primary affiliated billing organization is ALEXIAN BROTHERS SPECIALTY GROUP (NPI: 1720371669; TIN: 800710751) and primary practice location at 60007-3361.

Haryani's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 678 traditional Medicare patients, billed 2,530 HCPCS/CPT codes, and received $176,815 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,798 prescription claims across 535 beneficiaries totaling $2,906,729 in drug costs, led by Vyndamax (Tafamidis). DME data shows 216 claims. Open Payments data shows 83 records totaling $36,616. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $5,376 to $2,906,729. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $6,831 and ending at $10,182.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	255	449	$33,822
2018	1,331	2,609	$147,580
2019	1,801	3,771	$247,959
2020	1,399	3,210	$215,860
2021	1,153	2,839	$234,381
2022	887	2,377	$192,874
2023	653	2,071	$182,820
2024	678	2,530	$176,815

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	37	64	$5,376
2018	123	603	$49,446
2019	213	1,210	$168,145
2020	322	1,859	$337,675
2021	388	2,888	$735,711
2022	391	2,796	$1,054,279
2023	407	3,003	$1,379,924
2024	535	3,798	$2,906,729

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	36	$975
2019	N/R	227	$11,806
2020	N/R	69	$2,693
2021	N/R	241	$11,832
2022	33	425	$23,945
2023	33	478	$30,942
2024	N/R	216	$9,564

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	158	237	$110
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	120	350	$105
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	274	407	$77
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	147	149	$53
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	351	654	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	29	1,110	$836,723
Entresto	Sacubitril/Valsartan	391	27,659	$582,571
Jardiance	Empagliflozin	421	26,740	$512,379
Vyndaqel	Tafamidis Meglumine	13	390	$295,969
Eliquis	Apixaban	188	13,545	$262,610

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J2260	Injection, milrinone lactate, 5 mg	N	N/R	54	$3,539
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	73	$3,055
J1250	Injection, dobutamine hydrochloride, per 250 mg	N	N/R	19	$1,646
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	70	$1,323

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	79	$11,868	Boehringer Ingelheim Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	4	$24,748	United Therapeutics Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ashish Haryani, MD?

Tedicare shows public-source Medicare data for Ashish Haryani, MD (NPI 1245556547), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ashish Haryani, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ashish Haryani, MD?

Ashish Haryani, MD is linked to ALEXIAN BROTHERS SPECIALTY GROUP (billing NPI 1720371669) in the available physician profile data.

Does Ashish Haryani, MD have Open Payments data?

Ashish Haryani, MD has 83 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.